Ongoing trials in Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Ongoing trials in Alzheimer's disease.

Ongoing trials in Alzheimer's disease.

http://www.wikidata.org/entity/Q34074827

about

The status of ongoing trials for mild cognitive impairment.Protective activity of aromatic amines and imines against oxidative nerve cell death.

P2860

Q34204390-7373B331-983B-4143-A0C9-ACE46D5859B1 Q43840174-35DEDBEB-EAC4-4104-BCB5-0683CE1F9A74

P2860

Ongoing trials in Alzheimer's disease.

http://www.wikidata.org/entity/Q34074827

description

2000 nî lūn-bûn

@nan

2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

name

Ongoing trials in Alzheimer's disease.

@ast

Ongoing trials in Alzheimer's disease.

@en

Ongoing trials in Alzheimer's disease.

@nl

type

label

Ongoing trials in Alzheimer's disease.

@ast

Ongoing trials in Alzheimer's disease.

@en

Ongoing trials in Alzheimer's disease.

@nl

prefLabel

Ongoing trials in Alzheimer's disease.

@ast

Ongoing trials in Alzheimer's disease.

@en

Ongoing trials in Alzheimer's disease.

@nl

P1433

Q34074827-ADCBDF2E-DD90-4BBC-A493-349952EFFFFE

P1476

Q34074827-BCD0B753-ADD1-4D2D-8787-B8D1AD0363B4

P2093

Q34074827-53A6DA30-7C49-421B-BABE-44AB04E0BBBC

Q34074827-C404CA50-2A34-4983-AD9D-0D72B487938A

P2860

Q34074827-0A7E11B6-BC48-4E86-9AC4-09AB18534F0A

Q34074827-0B21E8E4-BE3E-4CDA-B2E2-27235E0F8B02

Q34074827-0BFF4A31-CA28-49B4-953B-B404B8D07F48

Q34074827-1A2B521F-0045-45CE-88F7-22FB313D0EF6

Q34074827-27A540E9-7ABB-4595-A26A-659FEFFC2D31

Q34074827-28EDF6CA-2959-4E04-915C-892D45BCD6B9

Q34074827-29313983-9C8A-4EA3-901C-69F789BEE427

Q34074827-2F542C78-64C3-44AA-8F8D-EFBC49C4DB1F

Q34074827-31AEAA93-F889-4E83-95BE-4E391C06B6DA

Q34074827-38A12B92-FC86-4219-9792-7B0C88D9CDA3

P304

Q34074827-C7479211-2878-437A-8A51-601BE0DB9FCE

P31

Q34074827-A9ABB795-9FEC-4C91-B402-DC86364BACF2

P356

Q34074827-E4E6B9BC-C0CE-4B04-90CB-9E96E7079926

P407

Q34074827-793E5EE9-F341-4683-9EB4-76E19B42B302

P433

Q34074827-EA7F3C69-0EEA-4149-9A38-AF9D4E57CD70

P478

Q34074827-BC7240AD-9F1E-49F4-AE83-984F283D7BA7

P577

Q34074827-4B9379C7-C454-4F1D-9542-B438B2B64170

P698

Q34074827-B22B6650-DE90-4C19-8DB5-B97772B9CB06

P921

Q34074827-D44CD2B1-1CF9-4AA0-915F-FA6FBA22E48C

P356

13543784.9.4.899

P1433

Expert Opinion on Investigational Drugs

P1476

Ongoing trials in Alzheimer's disease.

@en

P2093

Cutler NR

http://www.w3.org/2001/XMLSchema#string

Sramek JJ

http://www.w3.org/2001/XMLSchema#string

P2860

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Neuropathological stageing of Alzheimer-related changes

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease

Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides.

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

Safety and tolerability of CI-979 in patients with Alzheimer's disease.

Electrophysiological and cellular effects of estrogen on neuronal function.

Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease.

P304

899-915

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.9.4.899

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2000-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11060718

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease